Suzhou Ribo Life Science swings to FY26 H1 profit of RMB 23.45 million; revenue rises to RMB 419.74 millionPUBT·2 days ago, 06:14 AM06938-3.29%MDGL-1.83%
Suzhou Ribo Life Science board meets to review interim results, consider dividendPUBT·Aug 17 at 03:45 AM06938-3.29%
Madrigal Pharmaceuticals (MDGL) Is Up 9.1% After Wider Q2 Net Loss Highlights Costly MASH ExpansionSimplywall·Aug 9 at 06:38 AMMDGL-1.83%06938-3.29%
Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillationPUBT·Jul 28 at 06:58 AM06938-3.29%
Ribo reports vortosiran Phase IIa trial results for coronary artery diseaseWorldPharmaceuticals·Jul 23 at 06:38 AM06938-3.29%
10:11 ETRibo revela datos positivos del ensayo de fase 2a de vortosiranprnewswire·Jul 22 at 09:13 AM06938-3.29%
Suzhou Ribo Reports First Global Proof-of-Concept for siRNA FXI Therapy in CADTip Ranks·Jul 22 at 03:40 AM06938-3.29%
Suzhou Ribo files HKEX next-day return disclosing share repurchase at HKD 48.5 avg pricePUBT·Jul 14 at 05:53 AM06938-3.29%
Suzhou Ribo Life Science Signals Confidence With HK$9.3 Million Share BuybackTip Ranks·Jul 13 at 09:09 AM06938-3.29%
Suzhou Ribo files HKEX next-day return disclosing share buyback at HKD 49.85 average pricePUBT·Jul 13 at 08:54 AM06938-3.29%
Will siRNA MASH Candidate Nomination with Suzhou Ribo Change Madrigal Pharmaceuticals' (MDGL) Narrative?Simplywall·Jul 12 at 12:18 PM06938-3.29%MDGL-1.83%
Suzhou Ribo director Gan Liming lifts H-share stake with 6,800-share purchasePUBT·Jul 10 at 05:18 AM06938-3.29%
